
Parag Kolhe
Advertisement
Parag Kolhe is a principal scientist at Pfizer, Inc.
Articles by Parag Kolhe
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
2
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
3
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
4
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
5




